- active not recruitingPHASE2
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
This study is checking a new medicine called AOC 1020 for people with Facioscapulohumeral Muscular Dystrophy (FSHD). It's for people who were in an earlier study of this medicine. The aim is to see if it's safe and helps over a longer time.
United States · Canada · United Kingdom - active not recruitingPHASE2
Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1
This study is looking into a new treatment called Satralizumab for a type of muscular dystrophy called FSHD1. It aims to see if this medicine can reduce inflammation in the body and muscles, which might help slow down the disease.
Canada · France - recruitingPHASE3
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
This study is testing a new medicine called del-brax for people with Facioscapulohumeral Muscular Dystrophy (FSHD). Researchers want to see if it's safe and effective in improving or slowing down the condition. It involves receiving treatment every six weeks for over a year.
United States · Canada · Denmark